Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Notes Payables (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Notes Payables for 8 consecutive years, with $36.7 million as the latest value for Q4 2025.

  • Quarterly Notes Payables rose 19.24% to $36.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $36.7 million through Dec 2025, up 19.24% year-over-year, with the annual reading at $29.9 million for FY2025, N/A changed from the prior year.
  • Notes Payables for Q4 2025 was $36.7 million at Outlook Therapeutics, up from $29.9 million in the prior quarter.
  • The five-year high for Notes Payables was $36.7 million in Q4 2025, with the low at $12.0 million in Q1 2025.